NEW YORK, Jan. 9, 2026 /PRNewswire/ -- GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has dosed the first patient in its global Phase 3 Beeline trial of investigational...
Hence then, the article about grin therapeutics announces first patient dosed in global phase 3 beeline trial of investigational radiprodil for grin related neurodevelopmental disorder was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GRIN Therapeutics Announces First Patient Dosed in Global Phase 3 Beeline Trial of Investigational Radiprodil for GRIN-Related Neurodevelopmental Disorder )
Also on site :
- Several Denver-area gas stations pumped contaminated fuel this week, King Soopers warns
- Diesel was mistakenly distributed instead of regular unleaded at many Colorado gas pumps
- Man police shot in Brooklyn hospital was former NYPD officer, police said